You are here

Share:

Search Technologies

Showing 1-20 of 266 results found

Zirconium-89 PET Imaging Agent for Cancer

This technology is a new generation of rationally designed chelating agents that improve the complexation of Zirconium-89 for PET imaging of cancers.

Virus-Like Particles That Can Deliver Proteins and RNA

The present invention describes novel virus-like particles (VLPs) that are capable of binding to and replicating within a target mammalian cell, including human cells. The claimed VLPs are safer than viral delivery because they are incapable of re-infecting target cells. The National Cancer Institute's Protein Expression Laboratory seeks parties interested in licensing the novel delivery of RNA to mammalian cells using virus-like particles.

Video Monitoring and Analysis System for Vivarium Cage Racks

This invention pertains to a system for continuous observation of rodents in home-cage environments with the specific aim to facilitate the quantification of activity levels and behavioral patterns for mice housed in a commercial ventilated cage rack.  The National Cancer Institute’s Radiation Biology Branch seeks partners interested in collaborative research to co-develop a video monitoring system for laboratory animals.

Vaccine for BK Polyomavirus-associated Infections in Transplant Recipients

NCI researches identified a BK polyomavirus (BKV) virulent strain that causes chronic urinary tract infections, and the development of vaccine and therapeutic methods that would block BKV pathogenesis. The NCI Laboratory of Cellular Oncology, seek parties to license or co-develop this technology.

Use of the TP5 Peptide for the Treatment of Cancer

Increased cyclin-dependent kinase 5 (CDK5) activity has recently emerged as a contributor to cancer progression. Researchers at the National Cancer Institute (NCI) and at the National Institute of Neurological Disorders and Stroke (NINDS) have shown that TP5, a small peptide inhibitor of CDK5 modified to facilitate passage through the blood brain barrier (BBB), has potential therapeutic benefit in glioblastoma (GBM) and colorectal carcinoma (CRC). NCI is seeking parties interested in co-developing and/or licensing TP5 for its use in the treatment of cancers with aberrant CDK5 expression as a mono-therapy or in an adjuvant setting with current standard-of-care.

Use of Heterodimeric IL-15 in Adoptive Cell Transfer

Researchers at the National Cancer Institute (NCI) have developed a technology that provides methods of performing adoptive cell transfer (ACT), an immunotherapeutic approach for cancer treatment, by administering a heterodimeric Interleukin 15/Interleukin 15 receptor alpha (IL-15/IL-15Rα) complex (hetlL-15) in the absence of lymphodepletion, thereby eliminating any lymphodepletion-associated detrimental side effects.

Use of Cucurbitacins and Withanolides for the Treatment of Cancer

The National Cancer Institute's Laboratory of Experimental Immunology, Cancer Inflammation Program, seeks parties interested in collaborative research to co-develop, evaluate, or commercialize the use of certain cucurbatacins or withanolides in combination with pro-apoptotic agonists of TRAIL death receptors for cancer therapy.

Urine-based Diagnostic Assay for the Early Detection of Cancer

Researchers at the NCI have developed a urine-based diagnostic platform capable of predicting the onset of cancer. This high-throughput screening method quantifies metabolites to assess cancer risk, determine disease prognosis and monitor response to therapy.

Tumor Tissues Harboring Mutations in cAMP-specific Phosphodiesterases

The National Institute of Child Health and Human Development (NICHD), Division of Intramural Research, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize clinical samples with genetic mutations associated with endocrine tumors.

Treatment Regimens for hetIL-15

Researchers at the National Cancer Institute (NCI) developed a treatment regimens for cancer and HIV using heterodimeric IL-15 (hetIL-15). The regimens allow access to B cell follicles, germinal centers, and tumor sites that are difficult for drug entry. A combination therapy for HIV infection is also described using hetIL-15 and a conserved element vaccine. Researchers seek licensing and/or co-development research collaborations for development and commercialization of treatment regimens for HIV infection.

Treating JC Polyomavirus Infection and Associated Leukoencephalopathy

The National Cancer Institute seeks parties interested in collaborative research to co-develop or license methods of treating disorders related to polyomavirus, as well as vaccines for patients undergoing immunosuppressive treatment such as multiple sclerosis, rheumatoid arthritis, B cell cancers, and Crohn’s disease.

Transperineal Ultrasound-Guided Prostate Biopsy

The National Institutes of Health (NIH) Clinical Center (CC) seeks Cooperative Research and Development and/or license agreements for Transperineal Ultrasound-Guided Prostate Biopsy

Transgenic Mouse Model of Human Basal Triple Negative Breast Cancer

NIH scientists created and characterized an excellent mouse model for TNBC that shares important molecular characteristics of human TNBC making it highly useful for preclinical testing of drugs and novel therapies. This model may provide a valuable means of identifying new drugs and therapies that could be translated to human clinical trials.The NCI seeks parties interested in licensing this mouse model of prostate and triple-negative breast cancers to study cancer biology and for preclinical testing.

Transformation of Weak or Non-Immunogenic Antigens to Produce an Immune Response and Therapeutic Polypeptides for the Treatment and Prevention of Cancer

Researchers at the National Institute on Aging (NIA) have developed a novel strategy for rendering weakly or non-immunogenic, shared (between self and tumor) antigens immunogenic, or able to produce an immune response. Further, they have created therapeutic polypeptides comprising tumor-associated embryonic antigens and chemoattractant ligands. Cancers targeted by these developments include breast, renal, lung, ovarian, and hematological cancers.

Pages